[go: up one dir, main page]

SG11202005990RA - Process for providing pegylated protein composition - Google Patents

Process for providing pegylated protein composition

Info

Publication number
SG11202005990RA
SG11202005990RA SG11202005990RA SG11202005990RA SG11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA
Authority
SG
Singapore
Prior art keywords
protein composition
pegylated protein
providing
providing pegylated
composition
Prior art date
Application number
SG11202005990RA
Inventor
Wolfgang Koehnlein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202005990RA publication Critical patent/SG11202005990RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202005990RA 2017-12-29 2018-12-28 Process for providing pegylated protein composition SG11202005990RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17211124 2017-12-29
PCT/EP2018/097122 WO2019129876A1 (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Publications (1)

Publication Number Publication Date
SG11202005990RA true SG11202005990RA (en) 2020-07-29

Family

ID=60954809

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005990RA SG11202005990RA (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Country Status (7)

Country Link
US (2) US12208142B2 (en)
EP (1) EP3731871B1 (en)
JP (2) JP7137625B2 (en)
KR (1) KR102523239B1 (en)
CN (1) CN111741770A (en)
SG (1) SG11202005990RA (en)
WO (1) WO2019129876A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12208142B2 (en) * 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
JP7227633B2 (en) * 2017-12-29 2023-02-22 エフ. ホフマン-ラ ロシュ エージー. Methods for providing PEGylated protein compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
EP0452484B2 (en) 1989-11-06 2004-07-28 Cell Genesys, Inc. Production of proteins using homologous recombination
ATE156189T1 (en) 1989-12-22 1997-08-15 Applied Research Systems MODIFICATION OF ENDOGENE GENE EXPRESSION USING A REGULATORY ELEMENT USING HOMOLOGOUS RECOMBINATION
JP3051145B2 (en) 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
PT101031B (en) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
ATE225801T1 (en) 1992-07-13 2002-10-15 Bionebraska Inc METHOD FOR MODIFYING RECOMBINANT POLYPEPTIDES
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5886155A (en) 1997-06-18 1999-03-23 Bioresources International Inc. Purification of miraculin glycoprotein using tandem hydrophobic interaction chromatography
CZ300546B6 (en) 1999-01-29 2009-06-10 Amgen, Inc. Physiologically active conjugate, composition and process for preparing thereof
CZ299516B6 (en) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
JP3108767B1 (en) 1999-10-20 2000-11-13 農林水産省食品総合研究所長 Method for producing chib2 type chitinase
EP1404354A4 (en) * 2001-06-22 2005-04-20 Pharmacia Corp Chemically-modified progenipoietin conjugates
KR101145990B1 (en) * 2002-12-19 2012-08-23 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 Cyanovirin variant-polymer conjugates
AP2007003919A0 (en) * 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CL2008002053A1 (en) * 2007-07-17 2009-05-22 Hoffmann La Roche Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method.
EP2898900B1 (en) * 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US8697844B2 (en) * 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
KR20120118065A (en) 2010-02-12 2012-10-25 디에스엠 아이피 어셋츠 비.브이. Single unit antibody purification
ES2500048T3 (en) * 2010-09-14 2014-09-29 F. Hoffmann-La Roche Ag Procedure to purify pegylated erythropoietin
CN102453087B (en) 2010-10-22 2013-12-25 广东赛保尔生物医药技术有限公司 Purification and preparation method of mono-substituted PEG-EPO
EP2825205A1 (en) 2012-03-16 2015-01-21 Belrose Pharma Inc. Polymeric conjugates of c1-inhibitors
CN104513306B (en) 2014-12-15 2016-08-17 山西瑞亚力科技有限公司 The purification process of Apolipoprotein A1 and ApoAI protein injection antigen
HK1259368A1 (en) 2015-08-20 2019-11-29 F. Hoffmann-La Roche Ag Purification of fkpa and uses thereof for producing recombinant polypeptides
HRP20220041T1 (en) 2017-12-29 2022-04-15 F. Hoffmann - La Roche Ag Process for providing pegylated protein composition
US12208142B2 (en) * 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
JP7227633B2 (en) * 2017-12-29 2023-02-22 エフ. ホフマン-ラ ロシュ エージー. Methods for providing PEGylated protein compositions

Also Published As

Publication number Publication date
KR102523239B1 (en) 2023-04-18
EP3731871B1 (en) 2023-10-04
US20250170250A1 (en) 2025-05-29
CN111741770A (en) 2020-10-02
EP3731871C0 (en) 2023-10-04
JP2022169794A (en) 2022-11-09
US12208142B2 (en) 2025-01-28
KR20200104380A (en) 2020-09-03
JP7541555B2 (en) 2024-08-28
US20200323993A1 (en) 2020-10-15
JP7137625B2 (en) 2022-09-14
WO2019129876A1 (en) 2019-07-04
EP3731871A1 (en) 2020-11-04
JP2021508715A (en) 2021-03-11

Similar Documents

Publication Publication Date Title
IL288613A (en) Multispecific proteins
ZA201705960B (en) Proteins specific for cd137
DK3445788T3 (en) Novel bispecific polypeptides against cd137
ZA201704231B (en) Chimeric protein
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
ZA201708041B (en) Novel proteins specific for lag-3
SG11201704010UA (en) Fibroin-derived protein composition
SG11202006140TA (en) Process for providing pegylated protein composition
GB201608197D0 (en) Novel proteins
DK3737402T3 (en) Modificeret protein
GB201506223D0 (en) Chimeric protein
GB201711481D0 (en) Protein purification
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
IL258570A (en) Stable protein compositions
PT3806660T (en) Protein bar
ZA201901862B (en) Modified factor h binding protein
GB201600512D0 (en) Recombinant protein production
GB2558968B (en) G Proteins
GB201513033D0 (en) Proteins
ZA202003722B (en) Modified globin proteins
SG11202005990RA (en) Process for providing pegylated protein composition
GB201704006D0 (en) Modified globin proteins
SG11202005952TA (en) Process for providing pegylated protein composition